In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Novartis pays up to $5.3bn to acquire Takeda's Xiidra for dry eye

Executive Summary

Further boosting its ophthalmic pharmaceuticals portfolio, Novartis AG agreed to acquire Takeda Pharmaceutical Co. Ltd.'s dry eye drug Xiidra (lifitegrast) 5% topical solution and all assets associated with it.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)

Related Companies